These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31081535)

  • 1. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis.
    Liu B; Ou Q; Tang Y; Fu S; Liang P; Yu Y; Xu Z; Chen Y; Xu A
    Clin Rheumatol; 2019 Sep; 38(9):2519-2528. PubMed ID: 31081535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
    Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
    Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for lupus nephritis.
    Flanc RS; Roberts MA; Strippoli GF; Chadban SJ; Kerr PG; Atkins RC
    Cochrane Database Syst Rev; 2004; (1):CD002922. PubMed ID: 14973998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis.
    Deng J; Huo D; Wu Q; Yang Z; Liao Y
    Tohoku J Exp Med; 2012 Aug; 227(4):281-8. PubMed ID: 22820853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose rituximab in refractory lupus nephritis.
    Kotagiri P; Martin A; Hughes P; Becker G; Nicholls K
    Intern Med J; 2016 Aug; 46(8):899-901. PubMed ID: 27242250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
    Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis.
    Kagawa H; Hiromasa T; Hara T; Takaki A; Yamanaka R; Sada KE; Makino H
    Clin Exp Nephrol; 2012 Oct; 16(5):760-6. PubMed ID: 22492013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we manage lupus nephritis without chronic corticosteroids administration?
    Lightstone L; Doria A; Wilson H; Ward FL; Larosa M; Bargman JM
    Autoimmun Rev; 2018 Jan; 17(1):4-10. PubMed ID: 29108828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis.
    Nossent J; Raymond W; Kang A; Wong D; Ognjenovic M; Chakera A
    Lupus; 2018 Oct; 27(11):1838-1846. PubMed ID: 30092734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lupus nephritis.
    Hejaili FF; Moist LM; Clark WF
    Drugs; 2003; 63(3):257-74. PubMed ID: 12534331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis.
    Brugos B; Sebestyen L; Tarr T; Vincze Z
    Pharmazie; 2014 Jun; 69(6):442-4. PubMed ID: 24974578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
    Tanaka H; Tsugawa K; Suzuki K; Nakahata T; Ito E
    Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis.
    Dieker J; Schlumberger W; McHugh N; Hamann P; van der Vlag J; Berden JH
    Mol Immunol; 2015 Nov; 68(1):20-4. PubMed ID: 26597199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
    Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
    Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroids in Lupus Nephritis and Central Nervous System Lupus.
    Kamen DL; Zollars ES
    Rheum Dis Clin North Am; 2016 Feb; 42(1):63-73, viii. PubMed ID: 26611551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of proliferative lupus nephritis--a critical approach.
    Buhaescu I; Covic A; Deray G
    Semin Arthritis Rheum; 2007 Feb; 36(4):224-37. PubMed ID: 17067659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis.
    Zhou T; Zhang X; Lin W; Lin S
    J Pharm Pharm Sci; 2019; 22(1):365-375. PubMed ID: 31580800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
    Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
    Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.